—
—
In Stock
Cagrilintide is a novel therapeutic agent categorized as a dual amylin and calcitonin receptor agonist (DACRA). It mimics the hormone amylin, which complements insulin by regulating glucose, satiety, and energy balance—but improves on it with a longer half-life and reduced aggregation via design enhancements like lipid conjugation. How It Works: Mechanism of Action - Amylin analog: It triggers satiety signals through both homeostatic and reward pathways in the brain, enhancing feelings of fullness. - Acts on both amylin receptors (AMYR) and the calcitonin receptor (CTR), generating a compounded effect. Clinical Development & Efficacy As Monotherapy - In trials, cagrilintide alone achieved notable weight loss—around 7.8% in some studies. Combined with Semaglutide (CagriSema) - This combo, pairing an amylin analog with a GLP-1 agonist, has shown exceptional results: Phase II Trials - Achieved approximately 15.6% weight reduction over 32 weeks. Phase III Trials (REDEFINE 1 & 2) - REDEFINE 1 (68 weeks, non-diabetics): - CagriSema led to ~20.4% weight loss - Compare: semaglutide alone ~14.9%, cagrilintide alone ~11.5%, placebo ~3%.REDEFINE 2 (type 2 diabetes patients): - Achieved ~13.7% reduction vs. 3.1% with placebo. Metabolic Benefits Beyond Weight Loss - The combination therapy also produced improvements in blood pressure, glycemic control, lipid profiles, along with better physical function. Gastrointestinal side effects were typical but generally mild; cardiovascular safety parameters like heart rate remained stable. Market Context & Investor Reaction - The New England Journal of Medicine recently published the REDEFINE trial results in mid-2025, highlighting the impressive outcomes. - Despite these promising results, financial markets had a mixed reaction. Some coverage reported that weight loss averages (around 22.7%) slightly underperformed lofty expectations (~25%), leading to volatility in Novo Nordisk’s stock price. Summary Table Attribute Details Mechanism Dual agonist of amylin & calcitonin receptors (DACRA) Therapeutic Use Investigational obesity and type 2 diabetes therapy Monotherapy Effect ~7–8% weight loss Combo (CagriSema) ~20% weight loss (non-diabetics), ~13.7% (with T2D) Benefits Appetite suppression, metabolic improvements, overall safety
